Invivyd Reports Strong Q4 Revenue, $226.7M Cash, Advances VYD2311 to Phase 3 with Fast Track Designation

summarizeSummary

Invivyd, Inc. announced preliminary strong fourth-quarter 2025 revenue, a robust cash position of $226.7 million, and significant clinical progress for its lead COVID-19 antibody candidate, VYD2311, including Phase 3 trial initiation and Fast Track designation.

check_boxKey Events

• Preliminary Q4 2025 Revenue Growth

  Invivyd reported preliminary fourth-quarter 2025 PEMGARDA net product revenue of $17.2 million, representing 25% year-over-year and 31% quarter-over-quarter growth.

• Strong Cash Position

  The company ended 2025 with a preliminary $226.7 million in cash and cash equivalents, following over $200 million raised from financing transactions in the second half of 2025, providing sufficient operational runway.

• VYD2311 Phase 3 Trial Initiation

  Invivyd announced the initiation of its DECLARATION Phase 3 pivotal clinical trial for VYD2311, a vaccine-alternative antibody for COVID-19 prevention, with top-line data anticipated mid-2026.

• VYD2311 Granted Fast Track Designation

  The U.S. FDA granted Fast Track designation for VYD2311 in December 2025, which may expedite its development and review process for COVID-19 prevention in at-risk individuals.

auto_awesomeAnalysis

This 8-K filing signals significant positive momentum for Invivyd, Inc. The preliminary Q4 revenue growth for PEMGARDA demonstrates strong commercial execution. Crucially, the robust cash position of $226.7 million, bolstered by recent capital raises, substantially de-risks the company's financial outlook and provides ample runway for its ambitious clinical programs. Advancing VYD2311 into a pivotal Phase 3 trial, combined with FDA Fast Track designation, marks a critical milestone that could accelerate its path to market as a key COVID-19 prevention alternative. The expansion into RSV and measles antibodies further diversifies the pipeline, indicating future growth drivers beyond COVID-19. Investors should closely monitor the progress of the DECLARATION trial and subsequent pipeline developments.